Singapore, Nov. 11 -- Boehringer Ingelheim, one of the world's leading research-driven pharmaceutical companies, has announced that theblood clot-dissolving medicine Metalyse(R) (tenecteplase) has been approved in Singapore for the thrombolytic treatment of acute ischemic stroke (AIS). TheHealth Sciences Authority (HSA) approvedit for the treatment of adults with AIS within 4.5 hours from last known well.

Globally, AIS is one of the leading causes of death and long-term disability. In Singaporeit is the fourth leading cause of death, accounting for 5.8% of deaths, with 8.2% of stroke cases occurring in those below 50 years.Quick treatment is critical in the first hours after the onset of stroke symptoms to restore blood flow to the brain...